Coalition formed to fight cancer
San Francisco | 14 January 2016

Celgene, NantWorks and academic institutions have joined forces to form the National Immunotherapy Coalition (NIC) to help develop immunotherapies for cancer patients.

The NIC will launch the Cancer MoonShot 2020, which will provide access to more than 60 novel and approved agents under exploration in the fight against cancer.

The Quantitative Integrative Lifelong Trial (QUILT) programme will also be introduced. It is designed to harness all elements of the immune system, with the goal of achieving long-lasting remission for patients with cancer.

Representatives from Precision Biologics and Altor Bioscience have agreed to contribute their novel immunotherapy molecules, including adenovirus vaccines, and natural killer cells.

Dr Patrick Soon-Shiong, CEO of NantWorks, said: “I am hopeful that many more multinational pharma leaders in the immunotherapy space will agree to join this collaboration.”

Author: Tammy Facey



More IPPro Life Sciences | latest news
AstraZeneca enters China with Plendil
Hogan Lovells boosts capabilities in Japan
Morgan Lewis bags four from K&L Gates
Cobra and CPI enter £1.8 million project
Doctors Without Borders urges lower vaccine prices
IPPro Life Sciences
IPPRO ARCHIVES
BACK ISSUES ONLINE
COMPANY INFO
ABOUT US

THE TEAM


Copyright (C) 2013 Black Knight Media Ltd. All rights reserved. No reproduction without prior authorization